Hoffmann-la Roche Inc.

Roche Palo Alto LLC

Intermune, Inc.

Pharmasset, Inc.

Steven B Porter

Williamson Ziegler Bradford

Leonid Beigelman

Brad Owen Buckman

Scott D Seiwert

Antitsa Dimitrova Stoycheva

Vladimir Serebryany

Abel De La Rosa

Ellen S Yetzer

Michael D Rogers

William T Symonds

Patrick F Smith

Embodiments disclosed in the present application relate to a composition that can include a hepatitis C viral polymerase inhibitor, or pharmaceutically acceptable salt or prodrug thereof and a hepatitis C viral protease inhibitor, or pharmaceutically acceptable salt or prodrug thereof. Additional embodiments disclosed relate to methods for treating a disease condition such as a hepatitis C virus infection, liver fibrosis and/or impaired liver function with a hepatitis C viral polymerase inhibitor, or pharmaceutically acceptable salt or prodrug thereof and a hepatitis C viral protease inhibitor, or pharmaceutically acceptable salt or prodrug thereof.

Therapeutic composition

The embodiments provide compounds of the general Formulae I, II, III, IV, V, VI, VII, and X, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

Macrocyclic inhibitors of hepatitis C virus replication

Growing community of inventors

Mill Valley, CA, United States of America

Steven B Porter